Authors | Type of study | Type of RADT | Number of Patients | Sensitivity (%) | Specificity (%) |
---|---|---|---|---|---|
Denina et al. [9] | retrospective | LumiraDx TM Platform | 191 | 94.1 | 91.9% |
Ollier et. al. [6] | prospective | Biospeedia antigen test | 1009 | 69.9% | 99.9% |
Jung et al. [10] | prospective | Biosynex COVID-19 Ag BSS | 308 | 87.9% | 98.5% |
Carbonell -Sahuquillo et al. [3] | prospective | PanbioTM COVID-19 Ag Rapid Test Device | 357 | 70.5% | 100% |
Villaverde et al. [5] | retrospective, multicenter | Panbio COVID-19 Ag Rapid Test Device (Abbott Rapid Diagnostic) | 1620 | 45.4% | 99.8% |
Reichert et al. [4] | prospective | SD BioSensor Inc., Suwon, South Korea | 710 | 75% | 99.4% |
González-Donapetry et al. [11] | prospective | Abbott Rapid Diagnostics Jena GmbH, Jena, Germany | 440 | 77.78% | 100% |
Lanari et al. [12] | prospective (using 2 types of RAD kit) | COVID-19 Ag Fia Kit AFIAS COVID-19 Ag kit | 386 792 | 53.8% 86.4% | 99.7% 98.3% |
Mockel et al. [13] | prospective | Roche SARS-CoV-2 rapid antigen test, Penzberg, Germany | 202 | 72% | 99.4% |